



## CONTEMPORARY MEDICATION OF DEPRESSIVE STATES

**Author(s), affiliation** Cocîrla Iulia, Department of Pharmacology and Clinical Pharmacy, SUMPh "Nicolae Testemitanu"

### Introduction

In the last twenty years the rate of sale of antidepressant drugs has increased by more than 40%. The management of depression leads to extrapolation of clinical outcomes to ensure treatment efficacy and minimization of adverse effects.

### Keywords

depression, medication, antidepressants.

### Purpose

To study the medication of patients with depression during 2021 - 2022.

### Material and methods

The research was carried out in the Institute of Neurology and Neurosurgery. The study included a number of 117 patients diagnosed with depressive syndrome, using medical data recorded in clinical observation sheets and patients' dispensing records.

### Results

Among tricyclic antidepressants, the most widely used drug was amitriptyline. Second generation antidepressants - Selective Serotonin Reuptake Inhibitors - SSRIs (fluoxetine, fluvoxamine, paroxetine, sertraline, escitalopram), have relatively selective properties for inhibiting serotonin reuptake at the presynaptic level and produced adverse effects such as digestive (35%), neurological (26%), sexual dysfunction (12%), seizures (3%). Serotonin and norepinephrine reuptake inhibitors (SNRIs) are the newest drugs to be used (venlafaxine, desvenlafaxine, duloxetine), which produced similar adverse reactions to the previous ones

### Conclusions

The most used antidepressant drugs in medical practice among tricyclic antidepressants was amitriptyline; among SSRIs: fluoxetine, sertraline and escitalopram, and among SNRIs - venlafaxine.